Radioembolization for Rare Metastatic Disease

Abstract

Radioembolization has become a widespread treatment modality for both primary and metastatic hepatic malignancies. Although the majority of data and indication for yttrium-90 radioembolization have been for hepatocellular carcinoma and metastatic colorectal cancer, radioembolization with yttrium-90 has rapidly expanded into the treatment options for multiple tumor types with metastases to the liver. This article reviews the clinical data and expanding utilization of radioembolization for rare metastatic diseases with an emphasis on efficacy and safety.

Keywords

radioembolization - rare metastatic diseases - malignancy

Financial Disclosure

A.S.N.: nothing to disclose; G.N.: consultant (Angiodynamics, Boston Scientific, Guerbet, Incyte); B.J.S.: speaker (SIRTEX, Penumbra); C.P.: consultant (Boston Scientific, SIRTEX); A.P.: speaker (Penumbra, Bard); R.T.G.: consultant (SIRTEX).

Publication History

Received: 07 December 2020

Accepted: 05 March 2021

Article published online:
20 May 2021

• References

• 1 Khajornjiraphan N, Thu NA, Chow PK. Yttrium-90 microspheres: a review of its emerging clinical indications. Liver Cancer 2015; 4 (01) 6-15
• 2 American Cancer Society. Cancer Statistics Center. Accessed November 3, 2020 at: http://cancerstatisticscenter.cancer.org
• 3 Zaheer QA, Sherry R, Sharmi B, Sri Lekha B, Stacey TE, Faryal A. Pancreatic cancer with metastasis to liver: report of a case. Am J Gastroenterol 2018; 113: S1607-S1608
• 4 Ouyang H, Wang P, Meng Z. et al. Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine. Pancreas 2011; 40 (01) 120-125
• 5 Gulec SA, Wheeler J, Pennington K. et al. Chemotherapy with yttrium-90 microsphere selective internal radiation treatment and selective external radiation treatment in patients with metastatic pancreatic cancer. J Interv Oncol 2009; 2 (01) 84-92
• 6 Michl M, Haug AR, Jakobs TF. et al. Radioembolization with yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors. Oncology 2014; 86 (01) 24-32
• 7 Kim AY, Unger K, Wang H, Pishvaian MJ. Incorporating yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcinoma: a single center experience. BMC Cancer 2016; 16: 492
• 8 Kim AY, Frantz S, Brower J, Akhter N. Radioembolization with yttrium-90 microspheres for the treatment of liver metastases of pancreatic adenocarcinoma: a multicenter analysis. J Vasc Interv Radiol 2019; 30 (03) 298-304.e2
• 9 Bailey RE, Surapaneni PK, Core J. et al. Safety and efficacy of locoregional therapy for metastatic pancreatic ductal adenocarcinoma to the liver: a single-center experience. J Gastrointest Oncol 2019; 10 (04) 688-694
• 10 Kayaleh R, Krzyston H, Rishi A. et al. Transarterial radioembolization treatment of pancreatic cancer patients with liver-dominant metastatic disease using yttrium-90 glass microspheres: a single-institution retrospective study. J Vasc Interv Radiol 2020; 31 (07) 1060-1068
• 11 Gibbs P, Do C, Lipton L. et al. Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma. BMC Cancer 2015; 15: 802
• 12 Nezami N, Camacho JC, Kokabi N, El-Rayes BF, Kim HS. Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreatobiliary origin. J Gastrointest Oncol 2019; 10 (05) 944-956
• 13 Devulapalli KK, Fidelman N, Soulen MC. et al. 90Y radioembolization for hepatic malignancy in patients with previous biliary intervention: multicenter analysis of hepatobiliary infections. Radiology 2018; 288 (03) 774-781
• 14 Kennedy A, Brown DB, Feilchenfeldt J. et al. Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. J Gastrointest Oncol 2017; 8 (06) 1079-1099
• 15 Seedor RS, Eschelman DJ, Gonsalves CF. et al. An outcome assessment of a single institution's longitudinal experience with uveal melanoma patients with liver metastasis. Cancers (Basel) 2020; 12 (01) 117
• 16 Rowcroft A, Loveday BPT, Thomson BNJ, Banting S, Knowles B. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford) 2020; 22 (04) 497-505
• 17 Gonsalves CF, Eschelman DJ, Sullivan KL, Anne PR, Doyle L, Sato T. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol 2011; 196 (02) 468-473
• 18 Kennedy AS, Nutting C, Jakobs T. et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 2009; 27 (06) 682-690
• 19 Eldredge-Hindy H, Ohri N, Anne PR. et al. Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma: clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography. Am J Clin Oncol 2016; 39 (02) 189-195
• 20 Levey AO, Elsayed M, Lawson DH. et al. Predictors of overall and progression-free survival in patients with ocular melanoma metastatic to the liver undergoing Y90 radioembolization. Cardiovasc Intervent Radiol 2020; 43 (02) 254-263
• 21 Zheng J, Irani Z, Lawrence D, Flaherty K, Arellano RS. Combined effects of yttrium-90 transarterial radioembolization around immunotherapy for hepatic metastases from uveal melanoma: a preliminary retrospective case series. J Vasc Interv Radiol 2018; 29 (10) 1369-1375
• 22 Ponti A, Denys A, Digklia A. et al. First-line selective internal radiation therapy in patient with uveal melanoma liver metastases. J Nucl Med 2020; 61 (03) 350-356
• 23 Schelhorn J, Richly H, Ruhlmann M, Lauenstein TC, Theysohn JM. A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma. Acta Radiol Open 2015; 4 (04) 2047981615570417
• 24 Gonsalves CF, Eschelman DJ, Adamo RD. et al. A prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis. Radiology 2019; 293 (01) 223-231
• 25 Abbott AM, Doepker MP, Kim Y. et al. Hepatic progression-free and overall survival after regional therapy to the liver for metastatic melanoma. Am J Clin Oncol 2018; 41 (08) 747-753
• 26 Jaques DP, Coit DG, Casper ES, Brennan MF. Hepatic metastases from soft-tissue sarcoma. Ann Surg 1995; 221 (04) 392-397
• 27 Transue DL, Hackworth J, Johnson MS. et al. Multi-institutional experience treating metastatic soft tissue sarcomas using yttrium-90 microspheres. J Vasc Interv Radiol 2015; 26 (2, Suppl): S133, Abstract 290
• 28 Mauro D, Kim E, Tabori N. et al. Hepatic radioembolization for treatment of metastatic sarcoma as salvage therapy after failed chemotherapy: single center midterm results. J Vasc Interv Radiol 2016; 27 (3, Suppl): S154-S155, Abstract 341
• 29 Miller MD, Sze DY, Padia SA. et al. Response and overall survival for yttrium-90 radioembolization of hepatic sarcoma: a multicenter retrospective study. J Vasc Interv Radiol 2018; 29 (06) 867-873
• 30 Pierce DB, Johnson GE, Monroe E. et al. Safety and efficacy outcomes of embolization in hepatic sarcomas. AJR Am J Roentgenol 2018; 210 (01) 175-182
• 31 Ruohoniemi DM, Zhan C, Wei J. et al. Safety and effectiveness of yttrium-90 radioembolization around the time of immune checkpoint inhibitors for unresectable hepatic metastases. J Vasc Interv Radiol 2020; 31 (08) 1233-1241
• 32 Burnett NP, Akinwande O, Scoggins CR. et al. Comparison of yttrium-90 therapy for unresectable liver metastasis: glass versus biocompatible resin microspheres. J Radiat Oncol 2017; 6: 101-108
• 33 Demirelli S, Erkilic M, Oner AO. et al. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres. Nucl Med Commun 2015; 36 (04) 340-349
• 34 Yttrium 90 resin microspheres data collection in unresectable liver cancer: the RESIN Study (RESiN). Accessed November 12, 2020 at: https://clinicaltrials.gov/ct2/show/NCT02685631